# CED Cannabis Science Digest: Withdrawal, Sleep, and Pediatric Signals > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-withdrawal-symptom-management-pediatric-sleep-signals/ > **Published:** 2026-06-25T09:33:28-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:50:39-04:00 > **Clinical Summary:** Explore cannabis withdrawal symptom management with pediatric exposure and adolescent sleep risk signals in this June 2026 cannabis science digest. --- CED Clinical Relevance #59 Notable Clinical Interest June 25 already produced a stronger standalone insomnia-treatment article, but three additional verified papers still deserved preservation because they sharpen child-safety counseling, opioid-withdrawal conversations, and adolescent sleep-risk framing. Clinical Insight | CED Clinic Today’s strongest cannabis-science item was already handled as a full standalone report on CBD, CBN, and insomnia. What remained most useful was a companion digest preserving three lower-certainty but still clinically relevant public-health signals. One paper tracked the steep rise in accidental pediatric recreational-drug ingestions and found cannabinoids accounted for most cases. One cross-sectional analysis found that people using unregulated opioids who said they used cannabis for withdrawal were also more likely to report cutting back on opioid use, especially when pain was present. The third paper linked poor sleep quality with higher odds of adolescent cannabis, alcohol, and tobacco use. None of these items proves treatment efficacy. Their value is in risk framing, prevention thinking, and sharper follow-up questions. DigestSleepOpioid WithdrawalPediatricsSafety Audience Patients, caregivers, primary-care clinicians, addiction clinicians, sleep clinicians, and public-health readers Primary Topic Three verified cannabis-related public-health signals spanning pediatric accidental exposure, opioid-withdrawal self-management, and adolescent sleep-linked substance-use risk Source [Read the full study](https://pubmed.ncbi.nlm.nih.gov/42343328/) Table of Contents - [CED Cannabis Science Digest: 3 Withdrawal, Sleep, and Pediatric Exposure Signals](#CED_Cannabis_Science_Digest_3_Withdrawal_Sleep_and_Pediatric_Exposure_Signals) - [How to Read a Companion Digest After the Stronger Lead Already Ran](#How_to_Read_a_Companion_Digest_After_the_Stronger_Lead_Already_Ran)[A Better Reading Order for This Digest](#A_Better_Reading_Order_for_This_Digest) - [The Same Study Can Mean Different Things Depending on the Question Being Asked](#The_Same_Study_Can_Mean_Different_Things_Depending_on_the_Question_Being_Asked)[One Plant, Three Very Different Practical Questions](#One_Plant_Three_Very_Different_Practical_Questions) - [Counseling Gets Better When the Question Gets Narrower](#Counseling_Gets_Better_When_the_Question_Gets_Narrower) - [Accidental Exposure Is a Live Prevention Problem](#Accidental_Exposure_Is_a_Live_Prevention_Problem) - [Interesting Withdrawal Signal, Still Not a Treatment Trial](#Interesting_Withdrawal_Signal_Still_Not_a_Treatment_Trial) - [Poor Sleep May Be Part of the Cannabis-Risk Story](#Poor_Sleep_May_Be_Part_of_the_Cannabis-Risk_Story) - [All Three Papers Have Signal and Ceiling](#All_Three_Papers_Have_Signal_and_Ceiling) - [Public Health Tools Still Matter More Than Slogans](#Public_Health_Tools_Still_Matter_More_Than_Slogans) - [What Better Follow-Up Would Look Like](#What_Better_Follow-Up_Would_Look_Like) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## CED Cannabis Science Digest: 3 Withdrawal, Sleep, and Pediatric Exposure Signals CED Clinic’s main June 25 cannabis-science article covered the strongest sleep-treatment evidence. This companion digest preserves three additional public-health signals that matter for counseling and prevention: rising pediatric cannabinoid ingestions, self-reported [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) during opioid withdrawal, and the relationship between poor adolescent sleep and higher cannabis-use odds. What This Study Teaches Us This digest shows why [cannabis science](https://cedclinic.com/biphasic-effects-of-cannabis/) often helps most when it clarifies the next question instead of settling the treatment question. The pediatric poisoning paper shows where accidental exposure risk is concentrating. The opioid-withdrawal paper suggests a behavior pattern worth testing in real trials, not a result that should be mistaken for proof. The adolescent sleep paper reminds clinicians that cannabis risk conversations can miss the broader sleep-health context that may be driving use and worsening outcomes at the same time. Why This Matters Patients do not encounter cannabis in one clean lane. Families worry about accidental edible exposure. People living with pain and unstable opioid use may try cannabis to manage withdrawal. Teen substance-use prevention often overlaps with chronic sleep disruption. These papers matter because they improve those conversations without pretending the evidence is stronger than it is. They help separate where clinicians can speak confidently about risk from where they should stay cautious and hypothesis-driven. Study Snapshot Post Type Evidence digest using the canonical CED layout Items Reviewed 3 verified, nonduplicate, digest-eligible items Why This Is a Digest The day’s strongest fresh evidence already ran as a standalone insomnia full report, leaving a more useful companion role for lower-certainty but clinically relevant public-health signals Item 1 Poison-center surveillance of recreational-drug ingestions in children younger than 6 Item 2 Cross-sectional opioid-withdrawal and cannabis self-management analysis Item 3 Adolescent sleep-quality and cannabis-use association study Primary Dates June 24, 2026; June 24, 2026; June 20, 2026 Content Lanes Safety Signal; Research Brief; Safety Signal Main Takeaway Useful for counseling and prevention framing, not for treatment proof Related Reading 3 verified live CED Clinic internal links Clinical Bottom Line The most defensible companion publication today was a digest that keeps three public-health signals visible without overclaiming them. The practical message is that cannabinoids now dominate accidental recreational-drug ingestions in young children, self-reported [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) during opioid withdrawal deserves more rigorous study rather than easy endorsement, and adolescent cannabis prevention may be stronger when sleep quality is treated as part of the risk picture. Digest Contents - [Digest Card 1 | Pediatric Recreational-Drug Ingestions](#digest-card-2-digest-card-1-pediatric-recreational-drug-ingestions) - [Digest Card 2 | Cannabis Use During Opioid Withdrawal](#digest-card-3-digest-card-2-cannabis-use-during-opioid-withdrawal) - [Digest Card 3 | Adolescent Sleep Quality and Cannabis-Use Risk](#digest-card-4-digest-card-3-adolescent-sleep-quality-and-cannabis-use-risk) Why These Three Papers Belong Together Today’s main article addressed the strongest direct treatment-evidence question: which cannabinoids appear most useful for insomnia and which do not. These three additional papers matter for a different reason. They sharpen public-health, prevention, and counseling conversations that clinicians still have to navigate even when practice-changing treatment evidence is absent. That is why a digest works better than stretching any one of these items into a stronger headline than it can support. Readers need the signals preserved, but they also need the evidence limits left intact. Digest Card 1 | Pediatric Recreational-Drug Ingestions **Title:** Unintentional ingestion of recreational drugs among young children, 2000-2024. **Authors / source / date / lane:** Kristen Uskovich and colleagues, *BMC Public Health*, June 24, 2026. PMID 42343328. DOI 10.1186/s12889-026-28233-z. Content lane: Safety Signal. Source URL: https://pubmed.ncbi.nlm.nih.gov/42343328/ **What was investigated:** Investigators used National Poison Data System data from 2000 through 2024 to study accidental recreational-drug ingestions among U.S. children younger than 6 years old. **What it appeared to find:** Across 41,612 reported ingestions, cannabinoids accounted for 84.7% of cases. The ingestion rate increased 3,307% over the study period, and the sharpest growth after 2013 involved edible marijuana and psilocybin products. Most children had no or minor effects, but 5.0% had a major effect and six deaths were recorded across all recreational-drug categories. **Limitations and uncertainty:** This was poison-center surveillance, not a prospective pediatric cohort, and reports depend on recognition, reporting behavior, and coding quality. The paper is strong for trend detection, but it does not provide one clean bedside forecast for every individual exposure. **Why it is noteworthy:** Pediatric cannabis counseling often stays abstract. This paper gives a concrete reminder that accidental exposure is no longer a marginal issue and that edibles remain a central prevention problem. Digest Card 2 | [Cannabis Use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) During Opioid Withdrawal **Title:** Self-reported cannabis use to manage opioid withdrawal symptoms and reductions in opioid use among people who use unregulated opioids: a cross-sectional analysis. **Authors / source / date / lane:** Erica McAdam and colleagues, *Journal of [Cannabis Research](https://cedclinic.com/pediatric-cannabis-certification-care-children/)*, June 24, 2026. PMID 42343486. DOI 10.1186/s42238-026-00458-0. Content lane: Research Brief. Source URL: https://pubmed.ncbi.nlm.nih.gov/42343486/ **What was investigated:** Cannabis-using participants in Vancouver who also used unregulated opioids completed a cross-sectional questionnaire about whether they used cannabis to manage withdrawal symptoms and whether they had reduced opioid use during the same time period. **What it appeared to find:** People reporting cannabis use for opioid withdrawal were more likely to report reducing opioid use, with a stronger association in the subgroup living with moderate to severe pain. The authors framed this as support for testing cannabinoids in experimental withdrawal-focused trials. **Limitations and uncertainty:** This was self-reported, cross-sectional, and limited to people already using cannabis. It cannot prove cannabis caused opioid reduction, cannot rule out reverse causation or selection effects, and should not be read as evidence that cannabis is an established withdrawal treatment. **Why it is noteworthy:** The paper matters because it captures a real-world behavior clinicians already hear about. It is useful for research and counseling questions, but not for promising that cannabis will safely substitute for evidence-based opioid-use-disorder care. Digest Card 3 | Adolescent Sleep Quality and Cannabis-Use Risk **Title:** Independent and joint associations of chronotype and sleep quality with psychoactive substance use in adolescents. **Authors / source / date / lane:** Rodolfo Espinoza-Abad and colleagues, *Sleep Medicine*, PubMed date June 20, 2026. PMID 42330815. DOI 10.1016/j.sleep.2026.109095. Content lane: Safety Signal. Source URL: https://pubmed.ncbi.nlm.nih.gov/42330815/ **What was investigated:** A cross-sectional study of 1,311 adolescents examined whether chronotype, school schedule, and sleep quality were associated with alcohol, tobacco, and cannabis use. **What it appeared to find:** Poor sleep quality showed the most consistent association with higher odds of psychoactive-substance use across categories, including cannabis. Evening chronotype was associated with higher odds in simpler models, but those associations weakened after fuller adjustment. **Limitations and uncertainty:** This was not a cannabis-only study and not a longitudinal design. It cannot prove that poor sleep caused cannabis use, that cannabis caused poor sleep, or that one school-schedule change would alter substance-use patterns. **Why it is noteworthy:** Cannabis prevention is often framed only as a substance-use problem. This paper suggests sleep health may be one more useful intervention target in adolescent counseling, especially when clinicians are trying to understand repeated cannabis exposure in a broader behavioral context. How Strong Is This Evidence? All three items are peer-reviewed and primary-source verified. The pediatric-ingestion paper uses a large poison-center surveillance dataset, the opioid-withdrawal paper captures a real-world behavior pattern that merits testing, and the adolescent sleep paper uses a sizable school-based sample. That is enough for a cautious digest of public-health and counseling signals. Where This Paper Deserves Skepticism The surveillance paper is strong for trends but not for individual prognosis. The opioid-withdrawal study is cross-sectional self-report and cannot support causal or treatment claims. The adolescent sleep paper is multi-substance epidemiology rather than a cannabis-specific intervention study. Readers should preserve those distinctions or the digest becomes more certain than the papers themselves. What This Paper Does Not Show This digest does not show that cannabis is a validated treatment for opioid withdrawal, that fixing sleep alone will prevent [adolescent cannabis use](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/), or that every accidental pediatric cannabis exposure leads to severe harm. It also does not justify substituting these papers for evidence-based [addiction treatment](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/), pediatric emergency guidance, or individualized sleep care. How This Fits With the Broader Clinical Conversation Cannabis risk communication often fails because it swings between blanket reassurance and blanket alarm. These three papers argue for a narrower, more useful middle position: be precise about the exposure, the age group, and the question being asked. The pediatric-ingestion paper is about accidental exposure prevention. The opioid-withdrawal paper is about a real-world behavior pattern that should be studied more rigorously. The adolescent sleep paper is about risk clustering rather than proof of one-way causation. Taken together, they remind clinicians that prevention and counseling often improve when the conversation widens from cannabis alone to include packaging, pain, withdrawal, and sleep. Dr. Caplan’s Take *The pediatric-ingestion paper is the cleanest practical signal in this batch. If cannabinoids now account for most recreational-drug ingestions in young children, prevention messaging cannot stay generic. Storage, packaging, and edible-specific counseling need to be front and center.* *The opioid-withdrawal paper is clinically interesting because it describes behavior I hear about in real practice, but I would not let a cross-sectional association do more work than it can. It is a reason to ask better questions and support better trials, not a reason to present cannabis as established withdrawal care.* *The adolescent sleep paper reinforces something clinicians often see but under-document: poor sleep, unstable routines, and substance use can travel together. That makes sleep quality a worthwhile part of the cannabis-risk interview, even when the paper itself cannot tell us which factor came first.* What a Careful Reader Should Take Away These papers should make clinicians more specific, not more confident than the data allow. Talk concretely about child-proofing and edibles, distinguish self-reported opioid-reduction associations from treatment proof, and remember that adolescent cannabis risk may sit inside a broader sleep-health problem that deserves direct attention. Evidence Interpretation Guide ## How to Read a Companion Digest After the Stronger Lead Already Ran A companion digest is useful when the strongest treatment-evidence item has already been handled but other verified papers still add practical value. The point is not that these three papers are weak. The point is that they answer different questions than the lead insomnia article did. A careful read keeps each paper in its own lane: surveillance for child exposures, self-reported behavior during opioid withdrawal, and cross-sectional adolescent sleep-risk epidemiology. ### A Better Reading Order for This Digest **Start with the real-world setting**Ask whether the paper is about poison-center reports, cross-sectional self-report, or school-based epidemiology. Study setting tells you how close the findings are to bedside decisions. **Separate risk framing from treatment proof**A paper can be valuable for prevention or counseling without proving that cannabis helps, harms, or fixes a condition in a treatment sense. **Watch for causal overreach**Cross-sectional associations are often the easiest part of [cannabis science](https://cedclinic.com/biphasic-effects-of-cannabis/) to overread. They can show patterns worth following, but they rarely settle directionality. **Preserve the ceiling of the paper**If the study cannot support a clinical recommendation on its own, the summary should not pretend that it can. Clinical Framing Question Which of these three papers actually changes how a clinician should frame prevention, withdrawal, or adolescent risk conversations today? Patient-Friendly Question Do these studies prove cannabis is good or bad in one simple way, or do they mainly show that the answer depends on age, context, and what problem someone is trying to solve? The Bottom Line The safest interpretation is not that cannabis has one uniform public-health meaning. It is that child exposure, opioid withdrawal, and adolescent sleep-linked use each require their own evidence-labeled conversation. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, and critics can read the same data differently. These evidence-based lenses show where this trial is useful, where it remains uncertain, and how easily it can be overstated. Overview These papers matter differently to a parent worried about edibles, an addiction clinician hearing about withdrawal self-management, a school-health professional thinking about sleep, and a skeptical reader trying to keep causation separate from correlation. #### One Plant, Three Very Different Practical Questions A parent trying to keep edibles away from a toddler, a person using cannabis during opioid withdrawal, and a teenager with poor sleep are not facing the same cannabis question. This digest is useful because it keeps those situations separate. The practical value is not a single yes-or-no conclusion. It is a more precise understanding of where the risks and unknowns really sit. Lens takeaway Do not generalize one cannabis scenario onto every other one. #### Counseling Gets Better When the Question Gets Narrower For clinicians, the cleanest improvement here is language precision. The pediatric paper informs storage and edible counseling. The withdrawal paper informs how to discuss patient-reported cannabis use without presenting it as validated care. The adolescent paper supports adding sleep questions to a cannabis-risk interview. That is more useful than a broad statement that cannabis is either helping or harming across all contexts. Lens takeaway Use the paper that fits the question instead of stretching one paper across all questions. #### Accidental Exposure Is a Live Prevention Problem The pediatric-ingestion paper is the strongest prevention signal in this digest because it tracks a large real-world surveillance trend over time. The cannabinoid share of accidental recreational-drug ingestions is no longer trivial. That argues for concrete counseling on storage, packaging, and edible look-alikes rather than relying on vague safety warnings. Lens takeaway Child-proofing and edible-specific prevention deserve more direct attention. #### Interesting Withdrawal Signal, Still Not a Treatment Trial The opioid-withdrawal paper matters because it captures a real-world coping strategy in a high-risk population. That alone is worth understanding. But it should still be read as hypothesis-generating. A cross-sectional association between cannabis use for withdrawal and self-reported opioid reduction cannot replace randomized evidence or established opioid-use-disorder treatment. Lens takeaway Listen to the behavior signal without confusing it for proof of efficacy. #### Poor Sleep May Be Part of the Cannabis-Risk Story The adolescent paper suggests sleep quality deserves more attention in cannabis-risk discussions, especially when use co-travels with alcohol and tobacco exposure. That is clinically useful even without proving which factor came first. It also complements today’s lead insomnia report by showing that sleep matters not only as a treatment target in adults, but also as part of prevention thinking in younger populations. Lens takeaway Sleep belongs in prevention and screening conversations, not only in treatment plans. #### All Three Papers Have Signal and Ceiling A skeptical reader should notice that the strongest quantitative paper here is surveillance, not intervention. The most clinically provocative paper is the opioid-withdrawal study, but it is also the one most vulnerable to causal overreading. That does not weaken the digest. It means the right interpretation is layered, not binary. Lens takeaway Good skepticism preserves the usefulness of these papers by stopping them from being oversold. #### Public Health Tools Still Matter More Than Slogans The pediatric-ingestion findings point toward packaging, labeling, and storage policies rather than rhetorical arguments alone. The adolescent sleep paper points toward school-health and prevention systems that consider schedules and sleep burden, not just punishment for use. Even the withdrawal paper has policy relevance because it shows where formal research and harm-reduction systems are lagging behind what people are already doing. Lens takeaway Better public-health design beats louder generalized cannabis messaging. #### What Better Follow-Up Would Look Like The pediatric paper invites more product-specific exposure work and prevention-intervention testing. The withdrawal paper needs prospective and randomized follow-up. The adolescent sleep paper needs longitudinal designs that can test directionality and intervention effects. Those are meaningful next steps because they would raise the evidence ceiling on exactly the questions clinicians and families are already asking. Lens takeaway The next research upgrade is cleaner design, not stronger rhetoric. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=CED+Cannabis+Science+Digest%3A+3+Withdrawal%2C+Sleep%2C+and+Pediatric+Exposure+Signals&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-science-digest-june-25-2026-withdrawal-sleep-pediatric-signals%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-science-digest-june-25-2026-withdrawal-sleep-pediatric-signals%2F) [BlueSky](https://bsky.app/intent/compose?text=CED+Cannabis+Science+Digest%3A+3+Withdrawal%2C+Sleep%2C+and+Pediatric+Exposure+Signals%20https%3A%2F%2Fcedclinic.com%2Fcannabis-science-digest-june-25-2026-withdrawal-sleep-pediatric-signals%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Read the June 24, 2026 BMC Public Health paper on pediatric recreational-drug ingestions.](https://pubmed.ncbi.nlm.nih.gov/42343328/) Related Reading at CED Clinic Continue exploring the evidence Cannabis for Insomnia: CBN, CBD, and Why THC Falls Short Today’s main CED full report on the strongest sleep-treatment evidence, useful context for why this digest focuses on additional lower-certainty signals instead. Read the insomnia lead [Endocannabinoid System and Opioids: What a New Review Says About Pain and OUD](https://cedclinic.com/endocannabinoid-system-opioid-use-disorder-review/) Helpful context for the opioid-withdrawal paper because it explains how cannabinoid and opioid questions overlap without claiming cannabis is established OUD treatment. [Read the OUD context](https://cedclinic.com/endocannabinoid-system-opioid-use-disorder-review/) [Cannabis Caution as Study Finds Increased Psychosis Risk for Young People](https://cedclinic.com/cannabis-caution-as-study-finds-increased-psychosis-risk-for-young-people/) Relevant youth-risk context for the adolescent sleep paper because it keeps pediatric and adolescent cannabis counseling anchored to age-specific vulnerability rather than generic messaging. [Read the youth-risk context](https://cedclinic.com/cannabis-caution-as-study-finds-increased-psychosis-risk-for-young-people/) ## Frequently Asked Questions Why is this a digest instead of another standalone article? Because the strongest June 25 cannabis-science item already ran as a standalone insomnia full report. The clearest remaining publication value was a companion digest preserving three additional public-health and counseling signals. What is the clearest practical takeaway from the pediatric-ingestion paper? Cannabinoids now account for most reported accidental recreational-drug ingestions in children younger than 6, so storage, packaging, and edible-specific prevention deserve direct attention. Does the pediatric paper mean every accidental cannabis ingestion is severe? No. Most children in the poison-center dataset had no or minor effects, but a meaningful minority had major effects and the trend line still matters for prevention. Does the opioid-withdrawal paper prove cannabis helps people stop opioids? No. It found a self-reported association in a cross-sectional sample, which is useful for hypothesis generation but not strong enough to prove treatment benefit or causation. Why is the opioid-withdrawal paper still worth reading if it is not causal? Because it captures a real behavior pattern in a high-risk population and helps identify a question that deserves more rigorous clinical testing. What did the adolescent sleep paper actually find about cannabis? It found that poor sleep quality was consistently associated with higher odds of psychoactive-substance use, including cannabis, in adolescents, while chronotype effects were weaker after fuller adjustment. Does the adolescent paper prove poor sleep causes cannabis use? No. It is cross-sectional, so it cannot determine directionality. Poor sleep may contribute to use, use may worsen sleep, or both may travel with other stressors. How does this digest connect to today’s insomnia article? Today’s main article covered stronger treatment evidence about CBD, CBN, and THC for insomnia. This digest keeps three additional public-health and prevention signals visible without treating them as equivalent to treatment proof. Should patients use this digest to change treatment on their own? No. The digest is best used to sharpen questions for a clinician about child safety, withdrawal management, pain, and sleep rather than to make unsupervised treatment decisions. What kind of future research would most improve confidence here? Product-specific pediatric exposure studies, prospective or randomized work on cannabinoids during opioid withdrawal, and longitudinal adolescent sleep studies that can test directionality would all raise confidence meaningfully. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).